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Thanks to significant improvements in the precision, accuracy, and usability of continuous glucose 
monitoring (CGM), its relevance in both ambulatory diabetes care and clinical research is 
increasing. Here we address the latter perspective and derive provisional reporting 
recommendations.  CGM systems have been available since around the year 2000, and used 
primarily used in people with type 1 diabetes.  In contrast to self-measured glucose, CGM can 
provide continuous real-time measurement of glucose levels, alerts for hypoglycemia and 
hyperglycemia, and a detailed assessment of glycemic variability. Through a broad spectrum of 
derived glucose data, CGM should be a useful tool for clinical evaluation of new glucose-lowering 
medications and strategies. It is the only technology that can measure hyperglycemic and 
hypoglycemic exposure in ambulatory care, or provide data for comprehensive assessment of 
glucose variability. Other advantages of current CGM systems include the opportunity for improved 
self-management of glycemic control, with particular relevance to those at higher risk of or from 
hypoglycemia.  We therefore summarize the current status and limitations of CGM from the 
perspective of clinical trials, and derive suggested recommendations for how these should facilitate 
optimal CGM use and reporting of data in clinical research. 
[193 words]  
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Current status of CGM 
Technical development 
Since CGM was first introduced, the underlying technology has undergone a multi-level 
improvement, to the extent that it now has significant potential not only for routine ambulatory 
diabetes management, but also for clinical research. In contrast with early CGM systems (1), 
overall accuracy of current devices stands around ±10%, reflecting almost a two-fold improvement. 
Furthermore, accuracy, precision, and specificity continue to improve (2-6), with particular 
emphasis on the hypoglycemic range. Additionally, the achievement of mean absolute relative 
difference (MARD) values less than ±10% has made modern CGM a useful basis for insulin dose 
titration and adjustment (7,8), provided the sensors are deployed for longer periods of time (9).  
Other continuing technological advances relate to user-friendly software, interface and displays, 
and to better data management/analysis software, extending to automatic CGM real-time data 
transfer via internet and smartphones (10). 
Continuing technical issues include the need for periodic recalibration (generally every 12 hours), 
usually by using SMPG measurements (Table 1). Factory calibration would eliminate an important 
source of human error or omission, and simplify use and clinical trial reporting. For it to be 
possible, in vivo sensitivity differences in sensors as well as sensitivity degradation of the sensor 
over time (bio-fouling) need to be minimized. As yet, factory calibration is a reality only for the 
“flash” glucose monitoring system (not US FDA approved) (2), and does not appear to be a priority 
for many developers, who are more focused on improving accuracy (11). Implantable CGM 
sensors have the advantage of no repeated sensor replacement in the shorter term (up to 3 
months of duration for available sensors and increasing duration under development), mitigating 
errors arising from sensor insertion (12). However, implantation involves some discomfort and 
inconvenience and requires a higher level of medical intervention (13,14).   
CGM measurement parameters for assessment of glycemic status 
Studies on the use of CGM in clinical settings have often been aimed at determining the accuracy, 
precision, and reliability of the system (see next section).  It has however also been judged mature 
enough to be used as a tool for assessment of glycemic variation when using different glucose-
lowering interventions in people with type 1 or type 2 diabetes (15-19).  As the devices provide 
repeated glucose estimates at very short intervals, a wide variety of derived glycemic status 
parameters can and have been used for reporting purposes. Despite recommendations for 
standardization of endpoints, no consistency has been reached, limiting comparability between 
CGM systems (20, 21). Thus, some studies use historical parameters such as the mean amplitude 
of glucose excursion (MAGE), standard deviation or coefficient of variation about mean plasma 
glucose level, or the mean of daily difference (MODD) (22).  Meanwhile, others use mean glucose 
level, low/high blood glucose indices, the percentage of time over/under a certain glucose level, the 
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area under the glucose-time curve (AUC) at certain time points of defined glucose levels, the mean 
subsequent sensor glucose nadir, the median time to postprandial peak glucose levels, or the 
number of excursions above and below some level (15-19, 23-25) (Table 2). This variability of 
reporting variables presently makes comparisons of CGM results between studies difficult, thus 
limiting generalizability, and preventing comparisons among trials, including formal meta-analysis 
and network analysis.  
Blood glucose control in diabetes is conventionally measured on the basis of risk of hyperglycemia 
(risk of vascular damage), risk of hypoglycemia, and associated risk of lifestyle disruption from 
glucose variability. This suggests that CGM outputs should primarily be directed to measures of 
hyperglycemic and hypoglycemic exposure, as would be, for instance, the area of the curve 
above/below some glucose threshold. A particular issue with such a measurement is that 
arithmetic averaging does not weight greater excursions more strongly than more minor 
excursions. 
A small study comparing basal insulins in people with type 1 diabetes provides useful illustration of 
some of the data that can be generated to inform clinical research assessments, but also some 
limitations (22).  It includes expected measurements such as times and areas above/below certain 
blood glucose cut-offs for hyper- and hypo-glycemia, as well as the glucose profiles through the 
day. Daily profiling of glucose variance was useful in illustrating the 
pharmacokinetic/pharmacodynamics effect of the different basal insulins studied – indeed this is 
true clinical pharmacodynamics, since the intent of injected insulin is to control diurnal glucose 
profile. However, using a diurnal profile, rather than the pre- and post-prandial approach usual for 
SMPG, means that prandial glucose excursions are smoothed out because of people eating meals 
at different times. So while the hyperglycemic excursion measurement provides useful data, its 
visual display is problematic, except where meal times are standardized, something that is 
unrealistic in ambulatory care. 
The article however does provide detailed and useful variability analysis (22).  Any glucose data 
point can be influenced by daily time differences, interpersonal variability, day-to-day variance (or 
even weeks and years), as by other factors like erratic insulin absorption and lifestyle.  However, 
for CGM the individual, the time unit (day), and the time of day are known, and thus Bergenstal and 
colleagues could estimate not only overall variability but also day-to-day variance, inter-personal 
differences, intra-day variability, each independently of the others, as well as the residual variation. 
This parameter could be estimated for any time of the day just as for SMPG (e.g. pre-breakfast, 
pre-injection, 03:00 h), but CGM allows extending the time period of interest (e.g. night time). 
However, since in ambulatory care time standardization of daily events is difficult to achieve, longer 
periods of data recording may need to be restricted, for example nocturnal hypoglycemia from 
24:00-06:00 h, to avoid contamination from late and early meals and injections. 
Clinical evidence of CGM-associated benefits 
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Prerequisites for optimal implementation of CGM as used in the studies below include adequate 
patient education, training, and support in regard of sensor insertion, calibration, and real-time data 
interpretation (26). Adequate patient education also implies proper training of medical staff (Table 
1).   
Advantage of CGM over conventional self-monitoring has been reported by a number of clinical 
trials for improved HbA1c levels, decreased time in hypo-/hyper-glycemic ranges, and reduction of 
hypoglycemic events in people with type 1 diabetes (26-35). CGM has been shown to improve 
HbA1c levels both in poorly controlled people (26) and in those with ‘good’ baseline HbA1c levels 
(27-29). The analysis of frequency of hypoglycemic events with CGM has shown no increase in 
hypoglycemia in any trial examining change in HbA1c levels (23, 29-33). Moreover, two other trials 
studying the time spent in the low glucose range reported a decrease of time in this range in the 
CGM group in comparison with self-monitoring alone, despite one study finding no significant 
difference in hypoglycemic event rate (27,28).   
An important factor influencing positive effects on HbA1c levels or time/frequency of hypoglycemia 
is duration of CGM use. Several studies have shown that only continuous and long-term use of 
CGM is advantageous for people with type 1 diabetes (23, 27-29).  
Furthermore, some studies have shown psychosocial benefits und QoL improvements from CGM 
use in people with type 1 diabetes (34,35). 
 
CGM in clinical trials of glucose-lowering agents 
CGM would appear to have considerable potential in optimizing the performance of clinical trials.  
As noted above, a key aspect is that, since CGM has been shown to improve HbA1c and 
hypoglycemia in type 1 diabetes, best outcomes in clinical studies can only be assured by 
deploying it as a tool to inform insulin dose adjustment and indeed assist appropriate lifestyle 
adjustments. As CGM is increasingly employed in clinical practice, its similar use in clinical trials 
becomes necessary to ensure their generalizability.   
More specifically, however, clinical trials depend on an optimal assessment of relevant outcomes, 
which for diabetes, in essence, are hyper- and hypo-glycemic excursions. To date, CGM would be 
the first and only tool that can follow these variables throughout the day (36). Further, and 
particularly in type 1 diabetes, glucose profiles differ markedly in the same individual between days 
(intra-individual variance), and while SMPG can provide a sense of this variation, CGM is the first 
and only approach that can truly measure it. 
This is particularly true for studies in ambulatory care where glycemic variability (glycemic 
excursions of different kinds) or hypoglycemia reduction (time and extent in the hypoglycemic 
range) are under investigation. The analysis of data from six CGM studies on people with type 1 
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diabetes that included a reference blood glucose measurement concluded that CGM is a 
meaningful primary outcome measure for clinical trials in the appropriate settings (37). In that 
analysis, CGM-based outcomes had a high concordance with those based on classical reference 
methods. Even though this study found a certain degree of inaccuracy and underestimation of 
hypoglycemic/hyperglycemic extremes with CGM measurements, study design can compensate 
for these, either by augmenting patient number or by increasing study duration (37). Meanwhile, 
the wealth of information obtained on duration of such excursions cannot be obtained by other 
methods.   
In the last decade, a number of clinical trials have made use of CGM as an outcome evaluation 
method. For example, a single-day study of 26 type 2 diabetes patients assessed postprandial 
excursions and glycemic variability with CGM to determine efficacy differences between mitiglinide 
and sitagliptin, alone or in combination (38). The 24-hour CGM data analysis showed that both 
mitiglinide and the combination treatment produced lower glycemic variability (24-h glucose 
variability reflected by MAGE, SD and CV (%); p < 0.001) as well as decreased postprandial 
glucose excursion (AUC, p<0.001) and a more statistically significant change from baseline in 
postprandial hyperglycemia than sitagliptin alone (combination p=0.044; mitiglinide p<0.001).  
Moreover, the CGM measured mean 24-h blood glucose level decreased more significantly in the 
combination group than in the sitagliptin group (p=0.009), even when the time spent in the ideal 
glucose range (70-140 mg/dl) was not significantly improved in any group. Clearly, the wealth of 
data provided by CGM allows a deeper characterization of glucose variability than achievable by 
other methodologies. 
In short-term studies, CGM has been used to examine changes to postprandial glucose 
excursions.  In a 72-h study (allowing the time of some meals to be standardized and recorded) as 
many as 260 people with type 2 diabetes used CGM in a study of GLP-1 receptor agonist action 
(39).  The data showed significant effects on post-meal glucose increment as 0-4 h AUC, with 
confidence intervals suggestive of good statistical performance (95% CI vs degludec –21.1, –4.7 
mg/dl; vs liraglutide –10.1, 6.7 mg/dl). Data was presented for all three main meals.  Short-term (3-
day) CGM has also been use to compare the meal glucose excursions of conventional oral agents 
(40). 
CGM may, however, have even more utility in longer duration and more complex studies. As noted 
above, it has been used for comparison of measures of hyperglycemic and hypoglycemic 
excursions and aspects glucose variability, including graphical displays, in a study comparing a 
new basal insulin analogue to the established analogue in the treatment of people with type 1 
diabetes (22). This study is a good example of one of the advantages but also a disadvantage of 
CGM: the breadth of data it provides, and the large number of derived parameters that can be 
calculated (22).  Another study focused on hypoglycemia outcomes when the timing (or omission) 
of the last meal of the day is altered in people treated with basal insulin (41).  The study took place 
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over three days, repeated three times (9 days total recording time), in 20 people with type 2 
diabetes. CGM allowed the assessment of several aspects of hypoglycemia, and notably revealed 
that the principal effects of the meal timing changes were observed much later during sleep, 00.00 
and 06.00 h, a finding that would have been difficult to replicate with other methodologies. 
CGM was also used to characterize two therapeutic combinations in 63 newly diagnosed people 
with type 2 diabetes, which showed significant decreases from baseline values in derived plasma 
glucose parameters, differences between therapies, and in glucose fluctuations and hypoglycemia 
(42). 
Studies have also been performed using CGM in special populations.  One such was a small study 
(n=10) of a DPP-4 inhibitor in people having hemodialysis (43).  Area under the glucose-time curve 
(AUC) and the fasting plasma glucose were assessed showing statistically significant changes 
(uncontrolled) on both dialysis and non-dialysis days.   
A SGLT2-blocker study in people with type 1 diabetes used CGM to assess fasting plasma glucose 
(FPG), postprandial glucose excursion measured as AUC, the percentage of time over/under a 
certain level, and MAGE, among others (44). Statistically significant effects were shown for mean 
daily glucose level and time within the target glucose range, and time in gross hyperglycemia 
(>180 mg/dl) compared with placebo. 
 
Benefits and concerns of CGM 
Among the reasons why CGM could potentially be beneficial for clinical trials on glucose-lowering 
agents are its potential to reduce both duration of studies and number of participants, as suggested 
by some of the statistically significant results above (36). In ambulatory studies, CGM may come to 
replace SMPG profiles performed 7-9 times a day, with their problems as to timing and adherence 
(45, 46). Reasonably, much more data on hypoglycemic excursions should become available, both 
at night and during the day, though the statistical power of this data has yet to be tested.  
Moreover, with CGM much more detailed quantification of glycemic variability is possible, and with 
standardized meal times a more detailed description of postprandial glycemic excursions (47).  
However, CGM does have limitations (Table 1). One such is the lack of regulatory acceptance of 
CGM data in the USA except for adjunctive purposes, albeit this is similar to the situation for 
SMPG. Appropriate use of the technology requires a high level of education in the practical 
handling of the equipment and data management, for both patients and study personnel (36). 
Managing patient expectations is important to ensure balancing the additional effort associated 
with potential intrusiveness, data overload and alarm fatigue with increased confidence over 
diabetes management, ability to respond quickly to blood glucose information and reduced anxiety 
associated with diabetes management (34). Calibration still represents a clear complication to data 
analysis/interpretation, and is dependent on another patient-performed technology (SMPG). 
8 
 
Calibration of CGM at manufacture should solve this problem in time. Data management tools are 
still in evolution, being constantly improved by the development of new software, as well 
techniques for data transmission and sharing (14). Issues of accuracy and precision do still arise 
with CGM, at least by comparison with SMPG, and this may be more problematic at the extremes 
of glucose excursions (MARDs of most devices are above 10% at the extremes), an issue more for 
safety considerations rather than efficacy outcomes. It is therefore important that performance of 
systems used in clinical trials should be properly documented and in the public domain.   
To date, however, the greatest issue for CGM in clinical trials is that of end-point selection. The 
huge variability of reported outcomes limits comparability between trials and generalizability of 
study results (36).  
Lastly, there are concerns over CGM-driven glycemic outcomes. With one exception, none of the 
studies mentioned above report on blinding/masking of participants to CGM results (42). Therefore, 
even when patients were often instructed to continue with their usual exercise and diet routine (38, 
39, 42, 44), it cannot be completely discarded that glycemic improvement is not due to CGM 
informed decisions on self-management of diabetes. It is also possible that CGM naïve people 
would misinterpret the data to the detriment of their blood glucose control. For an accurate 
evaluation of the impact of glucose control agents on glycemic variation when using CGM, 
adequate patient education and blinding to the data are of great importance.  
 
Recommendations 
To be useful and valid in clinical trials use of CGM needs to be better standardized. To that end, 
we propose some suggestions on how CGM should be used in clinical studies, and how data 
should be reported (Table 3). 
Study protocol, Methods section 
To ensure high quality CGM data from clinical trials, the study protocol should detail different 
aspects of the estimation of plasma glucose through measurement of interstitial glucose levels: 
• The CGM system used needs to be described in detail, including device and manufacturer, and 
version number 
• Information on the setting and patient population: in-patient or out-patient setting, description of 
care team and program, whether a CGM education program is provided, characterization of 
participants and any specific indications for CGM; and whether CGM was used to modulate 
continuous subcutaneous insulin infusion (‘‘sensor-augmented pump’’), or as a component of a 
closed-loop system 
• Whether CGM was used real-time or blind: if real-time, were study participants familiar with use 
of CGM data to modulate insulin doses and lifestyle changes, or newly instructed 
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• Quality and characteristics of education/training of study participants in performing and 
interpreting CGM (if real-time) 
• Input of CGM outputs into any therapy dosing schedule or algorithm, both by the study 
participant and in telephone and clinic visits;  which actions are to be taken in response to low 
(or high) CGM read-outs  
• If relevant, details of any special meal or physical activity studies, type of time standardization 
and exclusion/handling parameters for data from subsequent time periods (e.g. overnight or for 
24 hours) within longer-term CGM data 
• Description of application of CGM: When was CGM initiated, and for how long performed  
• Methods of calibration and the devices employed to that aim 
• Definition of CGM adequate performance, namely protocol-determined criteria for data 
inclusion for analysis; for example, data might have to be 70 % complete in any time period 
analyzed over the projected duration of CGM use   
• The statistical tools used in preparing CGM data for reporting in the Results section (see 
below): this might include any averaging technique, cut-offs used to assess high and low 
glucose excursions, definitions of hypoglycemia, analyses of glucose variation and the 
terminology used to describe its different parameters, as well as methods of handling missing 
data 
• The status of any outcomes from CGM (primary, secondary, descriptive, safety). 
Results section: methodological and outcome measures 
The following topics should be addressed in the Results section: 
• Percentage of participants in each study arm having valid CGM data according to protocol-
determined criteria, and thus used in further statistical analysis (see above)  
• Analytical performance of CGM systems (correlation/deviation between CGM and SMPG 
values) 
• Classical clinical trial outcomes not dependent on CGM, including HbA1c, pre-breakfast self-
measured plasma glucose, hypoglycemia incidence and event rates according to severity and 
specific definitions, and adverse events    
• CGM output should be reported as plasma glucose, since even though glucose levels are 
measured in interstitial fluid, the output of CGM is calibrated to plasma glucose; similarly to 
SMPG where plasma glucose is reported from a whole blood specimen   
• Measures of glucose excursions: for standardization, we suggest the measurement of time and 
area above and below glucose thresholds, the latter being the best correlate of hyperglycemia 
and hypoglycemia exposure; we are not mandated to advise on appropriate cut-offs, but >140 
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mg/dl and <70 mg/dl approximately define the upper and lower limits of physiological glucose 
levels in healthy people; so for standardization purposes these should be reported even if other 
cut-offs are judged more relevant to study aims and are also included; hyperglycemic and 
hypoglycemic excursions have different clinical meaning and should be reported separately, 
even if also described as an aggregate ‘outside the normal range’;  other parameters such as 
mean of glucose excursions or number of dips into hypoglycemia may be considered at 
investigator (protocol-defined) discretion 
• Hyperglycemia cut-offs other than 140 mg/dl have been described in the literature, notably 8.0 
mmol/l and 180 mg/dl (21, 45).  Especially these may be more useful in people with type 1 
diabetes, so use of such cut-offs is additionally recommended, provided they are pre-defined 
and >140 mg/dl is also reported, and pending further discussion and consensus in the diabetes 
community 
• Hypoglycemia cut-offs other than 70 mg/dl (3.9 mmol/l) have been used both for sensitivity 
analyses and for primary hypoglycemia reporting (46, 47); use of the alternative cut-off of 56 
mg/dl (3.1 mmol/l) is therefore also recommended as an addition, pending further discussion; 
further cut-offs can be included if judged relevant to study aims, and according to study-
protocol 
• At present there is no standard for reporting hypoglycemia unawareness, where excursions to 
low glucose levels or different duration and extent are found on CGM without symptoms of 
hypoglycemia being reported;  we suggest that pending such standards, the number of days or 
nights at least one such episode occurs is reported and analyzed 
• Variability of glucose levels should only be employed for the precise analysis conducted; most 
useful are within-day, within-person daily variability (fluctuations across 24-hours, although 
sometimes a shorter part of the day may be analyzed), and within-person inter-day variability 
(erratic control) which can be reported for daily means or for particular time periods (e.g. 
nocturnal or pre-breakfast).  Furthermore, we recommend avoiding use of the term ‘variability 
of plasma glucose levels’. 
Discussion/Conclusion section 
An essential point in the discussion of a trial involving CGM use should be the potential impact of 
CGM on the study results, and hence their generalizability. Such areas might include lifestyle 
behaviors, dose and therapy changes, and hypoglycemia detection. This might include 
comparisons to previous research performed without CGM, or under different conditions of use. 
Furthermore, in line with recommendations for reporting of SMPG use in clinical research (45), 






In the appropriate setting, CGM may be a very useful tool for providing relevant information on 
hyperglycemia, hypoglycemia and glucose variability in clinical trials of glucose-lowering agents. 
This is particularly true to studies performed in ambulatory care and for those answering research 
questions related to variability and hypoglycemia reduction, both for people with type 1 and 2 
diabetes. However, the nature and extent of the data generated mean that the technology is 
presently ahead of our ability to establish which output parameters are relevant and most useful. In 
time, reduction of trial duration and participant numbers seem likely, offsetting some of the cost of 
the technology itself. We suggest that, pending broader and more formal consensus, the 
recommendations above should improve on the potential of CGM to advance our understandings 
of new and established therapies in quality clinical trials.   
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Domain Limitations of CGM 
Technical Need for regular recalibration by SMPG 
Lack of long-term stability 
Require user insertion – potential for error 
Not implantable 
Lower accuracy/precision at extremes of glycemia 
Evolving data communication systems 
Necessary process Extended period (continuous/long-term) of use 
Adequate professional (trial staff) training needed 
Adequate patient education, training, and support 
Management of patient expectations 
Limited available patient reported outcomes presently 
Blinding/masking of patients to CGM results 
Reporting  Diverse reporting variables for glucose excursions 
Lack of agreement on thresholds  
Diverse glucose variability reporting parameters 
Lack of system comparability 
Averaging with time hides glycemic excursions 
Visual display of glycemic excursions 
Diverse statistical tools including data averaging  
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Table 2.  Common metrics used in the analysis of CGM data  
Term/metric Detail and caveats 
System performance  
Mean absolute relative 
difference (MARD) 
Absolute deviation of CGM glucose measurement from a reference 
system.  May be calculated for different ranges of plasma glucose 
(e.g. low);   
Glucose control measures  
Mean blood (plasma) glucose 
(MBG, MPG);  Total area 
under glucose concentration 
curve 
Mean of data over a defined period.  Concatenates hyperglycemic 
and hypoglycemic excursions (cf HbA1c).  CGM, like self-measured 
glucose, is reported as plasma glucose, but the term ‘blood’ is often 
casually and incorrectly used 
Glucose concentration curve 
area above a pre-defined 
threshold for a defined time 
period 
Hyperglycemic deviation of glucose concentration multiplied by time; 
if the time base is the same as the time units, is the same as the 
average excursion; can be limited to a particular time of day, e.g. 
post-prandial; no weighting is given to more extreme levels  
Glucose concentration curve 
area below a pre-defined 
threshold for a defined time 
period 
Hypoglycemic deviation of glucose concentration multiplied by time; 
if the time base is the same as the time units, is equivalent to the 
average excursion; can be limited to a particular time of day, e.g. 
nocturnal; no weighting is given to more extreme levels;  
Time above or below some 
pre-defined threshold 
Usually given as percentage of some defined time period; takes no 
account at all of the magnitude of the excursion  
Time within some pre-defined 
range 
Usually given as percentage; choice of range open to manipulation 
to show good/poor results  
Time to peak (nadir) and peak 
(trough) level 
Conventional pharmacodynamic measures used in clinical 
laboratory challenge studies (e.g. meal challenges) 
Number of excursions above 
or below some pre-defined 
level 
A single excursion is time since crossing a threshold till return to that 
same threshold; fails to account for extended excursions 
Low/high blood (plasma) 
glucose indices 
Attempts to weight measurements for more extreme excursions; 
quantitative pathophysiological basis is uncertain 
Glucose variability measures  
Standard deviation (SD) or 
coefficient of variation (CV) of 
blood (plasma) glucose  
(SDBG, SDPG, CVBG, 
CVPG) 
SD from mean level, and CV as percentage of mean level; can be 
restricted to a time of day; independent of direction of glucose 
excursions 
Within-day, within person 
glucose variability 
A measure of mean changes usually over 24-hours, but can be 
restricted to other periods 
Between day, within person 
glucose variability (erratic 
glucose control) 
May use variability between the average for each day in one person, 
but can be restricted to other time intervals (e.g. nocturnal, pre-
breakfast, pre-dosing);  
Mean of the daily differences 
(MODD) Similar to previous parameter 
Mean amplitude of the 
glucose excursion (MAGE) 
Direction-independent (absolute) deviation from the mean glucose 
level (or from some other level, baseline or pre-determined) ignoring 
levels within 1SD 
Graphical displays Combined display by time of glucose control (mean of time) and 
between person, between day variability (study SD) at all time 
points; likely to create certain average basal and post-meal values 
due to between and within person variation in times of eating, thus 
flattening glucose excursions  
Other parameters have been proposed such as M-value, J-index, CONGA, ADRR, Lability/HYPO 
score, and GRADE, but have not been widely adopted.  See references (48, 49) 
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Table 3. Summary of recommendations on reporting of CGM methods and results when 
used in clinical trials 
Manuscript 
Section 
Information domain Example of detail 
 Introduction Purpose of CGM in 
study 
Secondary endpoints, hypoglycemia detail  
 Methods 
  
Make and version of 
CGM technology 
Manufacturer; read-out system 
Calibration methodology 
Criteria for successful use in the individual  
  






In-patient or ambulatory care   
Education to participants and investigators 
Injection therapy and dose algorithms; meal-time dose 
calculator; open-loop pump; closed loop functions 
Real-time or blinded  
Duration/timing of implementation  
  Classic glucose control 
data 
Including HbA1c, pre-breakfast SMPG, hypoglycemia 




Use of any averaging function 
Statistical outputs such as time in range and area above and 
below cut-offs; other outputs 
Parameters of glucose variability and how they are 
calculated 
Whether outputs are primary, secondary, or 
observational/safety 
Definitions and standards of hypoglycemia used 
Results 
Methodological 
Percent of participants with successful CGM implementation, 
duration of implementation 
Deviation between CGM and SMPG calibration 
measurements 
Use of CGM in dose or therapy changes 
 Classic glucose control 
outcomes 
See Methods above 
 
CGM outcomes 
Time in/out of range, and area/average glucose out of range 
high and low separately using default cut-offs of 140 mg/dl 
and 70 mg/dl 
Similar data using cut-offs of investigator choice appropriate 
to study question and technology under investigation 
CGM-based hypoglycemia data by time of day as 
appropriate to study, and to include glucose nadirs and 
presence or absence of symptoms during low excursions 
Within-patient, within-day glucose variability, and between 
day (average day) within-patient variability.  Such other 
within-patient variability for defined time periods (e.g. night or 
pre-breakfast) as pre-determined and appropriate to study.  
Discussion  Impact of CGM findings on study findings using conventional 
measures 
Generalizability of findings to people not using CGM (if real-
time and dose/therapy adjustment utilized) 
Limitations of CGM: extent of usable data, calibration 
findings, extreme glucose excursions 
 
